Conference Coverage

Rapid culture, stewardship improve S. aureus bacteremia outcomes


 

AT ASM MICROBE 2017

– Community hospitals could see positive outcomes using a Staphylococcus aureus bacteremia strategy that combines rapid blood cultures to speed diagnosis with antibiotic stewardship to guide treatment.

“I was pleased to see we were able to replicate the positive outcomes observed in studies from large tertiary care centers with our small cohort,” Marijo Roiko, PhD, microbiology program director for pathology and laboratory services at Altru Health System in Grand Forks, N.D., said in an interview.

Dr. Roiko and colleagues compared 33 patients diagnosed and treated prior to the strategy with 33 others following its implementation. A total of 13 patients, or 39% of each cohort, developed potentially fatal methicillin-resistant S. aureus (MRSA) bacteremia. Patients’ average age ranged from 60 to 64 years, and about two-thirds of each group were men.

The investigators reported that 30-day all-cause mortality decreased from 15.6% to 13.3% after the protocol. In addition, 30-day readmission rates decreased from 25% to 11% of the group diagnosed and managed with the new strategy. Dr. Roiko presented these and other findings from the chart review at the annual meeting of the American Society for Microbiology.

Overall, the average length of stay decreased from 13 days to 10 days among the patients with S. aureus bacteremia. Among the subgroup of patients with MRSA, the length of stay dropped from 15 to 12 days. Among those with methicillin-susceptible S. aureus infections, 11 days decreased to 9 days after institution of the protocol.

The researchers also looked at time to antibiotic deescalation, and the average time decreased from 3 days to 1 day with the new strategy.

“These results demonstrate the utility of rapid testing from positive blood cultures and antibiotic stewardship for patients with Staph. aureus bacteremia,” Dr. Roiko said.

In terms of return on investment, the estimated cost savings associated with the 3-day reduction in length of hospital stay was sufficient to cover the increased capital expenditures and reagent costs, the researchers found. They estimated these increased costs as $78,960, excluding ICU and ancillary charges. The approximate $4,290 saved per day multiplied by 33 patients means the new protocol saved a total of $141,570.

Traditionally, patients with a positive blood culture of S. aureus had a gram stain, followed by provider notification when positive. Targeted antibiotic therapy was either administered at this point or held for culture-based identification and susceptibility testing. In the new protocol, a rapid culture identification panel (FilmArray BCID) is added at the time of gram staining. Positive results are reported to both the provider and pharmacist. Targeted therapy is then either administered or held based on culture-based susceptibility testing (species identification is determined as needed).

The current study findings add to a literature already supporting use of rapid blood cultures and/or stewardship guidance to address S. aureus bacteremia in academic and tertiary care centers (J Clin Microbiol. 2016;54:2455-63; Clin Microbiol Infect. 2015;21:313-22, and Clin. Infect. Dis. 2015;61:1071-80.

Dr. Roiko had no relevant financial disclosures.

Recommended Reading

CDC: Some Shigella strains show reduced ciprofloxacin susceptibility
MDedge Family Medicine
Monotherapy as good as combo for antibiotic-resistant infections in low-risk patients
MDedge Family Medicine
Hospital infections top WHO’s list of priority pathogens
MDedge Family Medicine
Each added day of pediatric MRSA bacteremia upped complication risk 50%
MDedge Family Medicine
Adjunctive rifampicin doesn’t improve any outcome in S. aureus bacteremia
MDedge Family Medicine
VIDEO: Rifamycin matches ciprofloxacin’s efficacy in travelers’ diarrhea with less antibiotic resistance
MDedge Family Medicine
VIDEO: Registry study will follow 4,000 fecal transplant patients for 10 years
MDedge Family Medicine
Molecular tests for GAS pharyngitis could spur overuse of antibiotics
MDedge Family Medicine
Ribaxamase prevented C. difficile infections by protecting microbiome
MDedge Family Medicine
When fecal transplants for C. diff. fail, try, try again
MDedge Family Medicine